Celica Biomedical

Executive Summary

Celica Biomedical is a private European biotechnology company headquartered in Ljubljana, Slovenia, with a dual focus on oncology and diagnostics. Founded in 2000, the company specializes in understanding astrocyte physiology in the central nervous system (CNS) and its role in CNS trauma, metabolism, and neurodegenerative diseases. By targeting astrocytic dysfunction, Celica aims to develop novel therapies for CNS disorders. Additionally, the company is advancing dendritic cell-based cancer vaccines and cell-based advanced therapy medicinal products (ATMPs). Despite being established for over two decades, Celica remains in a private, non-public stage with no disclosed funding rounds, valuation, or commercial products. The company's research aligns with emerging trends in neuro-oncology and immuno-oncology, leveraging expertise in exocytosis and fusion pore dynamics in secretory cells. However, the lack of publicly available pipeline details, clinical trial data, or financial information limits visibility into its near-term prospects. Celica's ability to translate its foundational research into clinical candidates will be critical for future growth and partnership opportunities.

Upcoming Catalysts (preview)

• TBDPreclinical data readout for lead astrocyte-targeted therapy40% success
• TBDPartnership or licensing deal for dendritic cell vaccine platform30% success
• TBDGrant or non-dilutive funding announcement50% success